LRRFIP1 and pancreatic neoplasm: As shown in Table 1, clinical T stage (Hazard ratio (HR) = 2.040, 95% CI 1.082–3.850, p = 0.028), N stage (HR = 2.106, 95% CI 1.254–3.539, p = 0.005), residual tumor (HR = 1.625, 95% CI 1.044–2.530, p = 0.032), and anatomic neoplasm subdivision (HR = 2.332, 95% CI 1.291–4.213, p = 0.005), radiation therapy (HR = 0.502, 95% CI: 0.295–0.856, p = 0.011), primary therapy outcome (HR = 0.371, 95% CI 0.228–0.603, p < 0.001), and LRRFIP1 (HR = 1.716, 95% CI 1.129–2.608, p = 0.012) were significantly correlated with the overall survival of pancreatic cancer patients.